216 related articles for article (PubMed ID: 15362954)
1. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2).
Janvilisri T; Shahi S; Venter H; Balakrishnan L; van Veen HW
Biochem J; 2005 Jan; 385(Pt 2):419-26. PubMed ID: 15362954
[TBL] [Abstract][Full Text] [Related]
2. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
Janvilisri T; Venter H; Shahi S; Reuter G; Balakrishnan L; van Veen HW
J Biol Chem; 2003 Jun; 278(23):20645-51. PubMed ID: 12668685
[TBL] [Abstract][Full Text] [Related]
3. Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.
Alqawi O; Bates S; Georges E
Biochem J; 2004 Sep; 382(Pt 2):711-6. PubMed ID: 15139851
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
5. Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells.
Eddabra L; Wenner T; El Btaouri H; Baranek T; Madoulet C; Cornillet-Lefebvre P; Morjani H
Oncol Rep; 2012 Jan; 27(1):232-7. PubMed ID: 21935580
[TBL] [Abstract][Full Text] [Related]
6. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
7. pH-Dependent transport of pemetrexed by breast cancer resistance protein.
Li L; Sham YY; Bikadi Z; Elmquist WF
Drug Metab Dispos; 2011 Sep; 39(9):1478-85. PubMed ID: 21628496
[TBL] [Abstract][Full Text] [Related]
8. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Ozvegy C; Váradi A; Sarkadi B
J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
[TBL] [Abstract][Full Text] [Related]
9. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
10. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
11. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
[TBL] [Abstract][Full Text] [Related]
12. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
13. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
14. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
15. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
Telbisz Á; Hegedüs C; Váradi A; Sarkadi B; Özvegy-Laczka C
Drug Metab Dispos; 2014 Apr; 42(4):575-85. PubMed ID: 24384916
[TBL] [Abstract][Full Text] [Related]
17. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH
Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904
[TBL] [Abstract][Full Text] [Related]
18. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
[TBL] [Abstract][Full Text] [Related]
19. Valproic Acid-Induced Upregulation of Multidrug Efflux Transporter ABCG2/BCRP via PPAR
Kukal S; Bora S; Kanojia N; Singh P; Paul PR; Rawat C; Sagar S; Bhatraju NK; Grewal GK; Singh A; Kukreti S; Satyamoorthy K; Kukreti R
Mol Pharmacol; 2023 Mar; 103(3):145-157. PubMed ID: 36414374
[TBL] [Abstract][Full Text] [Related]
20. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
